help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on December 7, 2004
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2004-1672
A more recent version of this article appeared on February 1, 2005
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
90/2/805    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saravanan, P.
Right arrow Articles by Dayan, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saravanan, P.
Right arrow Articles by Dayan, C. M.

Submitted on August 20, 2004
Accepted on November 29, 2004

Partial substitution of thyroxine with tri-iodothyronine in patients on thyroxine replacement therapy: results of a large community-based randomised controlled trial

Ponnusamy Saravanan MB, MRCP,, Dawn J. Simmons, Rosemary Greenwood BSc,, Tim J. Peters PhD,, and Colin M. Dayan MBBS, PhD*

Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, University of Bristol; Research and Effectiveness Support Unit, Bristol Royal Infirmary; Academic Unit of Primary Health Care, Department of Community Based Medicine, University of Bristol

* To whom correspondence should be addressed. E-mail: colin.dayan{at}bris.ac.uk.

Conflicting results have recently been published about the benefits of combined thyroxine (T4) and triiodothyronine (T3) in treating hypothyroid patients. However these studies may have been underpowered to detect differences in psychological well-being specifically related to thyroxine replacement. We conducted a large, double-blind, randomized controlled trial of partial substitution of 50 µg of T4 by 10 µg of T3 (T3) vs. placebo (T4 alone - 50 µg of T4 replaced) in 697 hypothyroid patients. Thyroid function showed a rise in the TSH (132%), a fall in Free T4 (35%, P < 0.001) and unchanged basal Free T3 levels (P = 0.92). At 3 months there was a large (39%) "placebo effect" improvement in "psychiatric caseness" defined by the General Health Questionnaire 12 score (GHQ 12) in the control group compared with baseline and this was sustained at 12 months. Differences vs. the intervention (T3) group were more modest with improvements in GHQ caseness (OR - 0.61; 95%CI: 0.42, 0.90; P = 0.01) and HADS anxiety scores at 3 months (P < 0.03) but not GHQ Likert scores, HADS depression, thyroid symptoms or visual analog scales of mood and the initial differences were lost at 12 months. These results may be consistent with a subgroup of patients showing transient improvement following partial substitution with T3 but do not provide conclusive evidence of specific benefit from partial substitution of T4 by T3 in patients on thyroxine replacement. They also emphasize the large and sustained "placebo effect" that can follow changes in thyroid hormone administration.
Key words: Psychological wellbeing • Tri-iodothyronine • Thyroxine • Hypothyroidism • Thyroid hormone replacement • GHQ-12 • randomised controlled trial




This article has been cited by other articles:


Home page
 JAMAHome page
J. Jonklaas, B. Davidson, S. Bhagat, and S. J. Soldin
Triiodothyronine Levels in Athyreotic Individuals During Levothyroxine Therapy
JAMA, February 20, 2008; 299(7): 769 - 777.
[Abstract] [Full Text] [PDF]

Home page
 PsychosomaticsHome page
R. T. Joffe, M. Brimacombe, A. J. Levitt, and A. Stagnaro-Green
Treatment of Clinical Hypothyroidism With Thyroxine and Triiodothyronine: A Literature Review and Metaanalysis
Psychosomatics, October 1, 2007; 48(5): 379 - 384.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Saravanan, T. J. Visser, and C. M. Dayan
Psychological Well-Being Correlates with Free Thyroxine But Not Free 3,5,3'-Triiodothyronine Levels in Patients on Thyroid Hormone Replacement
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3389 - 3393.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. P. Walsh, L. C. Ward, V. Burke, C. I. Bhagat, L. Shiels, D. Henley, M. J. Gillett, R. Gilbert, M. Tanner, and B. G. A. Stuckey
Small Changes in Thyroxine Dosage Do Not Produce Measurable Changes in Hypothyroid Symptoms, Well-Being, or Quality of Life: Results of a Double-Blind, Randomized Clinical Trial
J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2624 - 2630.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Grozinsky-Glasberg, A. Fraser, E. Nahshoni, A. Weizman, and L. Leibovici
Thyroxine-Triiodothyronine Combination Therapy Versus Thyroxine Monotherapy for Clinical Hypothyroidism: Meta-Analysis of Randomized Controlled Trials
J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2592 - 2599.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. F. Escobar-Morreale, J. I. Botella-Carretero, F. E. del Rey, and G. M. de Escobar
Treatment of Hypothyroidism with Combinations of Levothyroxine plus Liothyronine
J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4946 - 4954.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society